ICU Medical, Inc. (NASDAQ:ICUI) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have received an average recommendation of “Moderate Buy” from the five ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $179.3333.

A number of research firms recently commented on ICUI. Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a research note on Thursday, January 22nd. Piper Sandler lifted their price target on ICU Medical from $172.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, February 20th. Wall Street Zen upgraded ICU Medical from a “hold” rating to a “buy” rating in a report on Sunday, February 15th. Finally, KeyCorp increased their price objective on ICU Medical from $175.00 to $180.00 and gave the company an “overweight” rating in a research report on Friday, February 20th.

ICU Medical Price Performance

ICUI stock opened at $133.34 on Tuesday. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.39 and a quick ratio of 1.15. ICU Medical has a one year low of $107.00 and a one year high of $160.29. The stock has a market cap of $3.29 billion, a PE ratio of 6,670.34, a P/E/G ratio of 1.90 and a beta of 0.79. The firm has a 50 day simple moving average of $148.93 and a two-hundred day simple moving average of $138.06.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Thursday, February 19th. The medical instruments supplier reported $1.91 EPS for the quarter, topping analysts’ consensus estimates of $1.68 by $0.23. ICU Medical had a net margin of 0.03% and a return on equity of 7.33%. The firm had revenue of $535.94 million for the quarter, compared to analyst estimates of $541.20 million. During the same quarter in the prior year, the firm earned $2.11 EPS. The business’s revenue for the quarter was down 14.1% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, analysts predict that ICU Medical will post 4.11 EPS for the current fiscal year.

Institutional Investors Weigh In On ICU Medical

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in shares of ICU Medical by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 2,714,746 shares of the medical instruments supplier’s stock valued at $387,313,000 after purchasing an additional 89,755 shares during the last quarter. Janus Henderson Group PLC lifted its stake in ICU Medical by 4.2% in the fourth quarter. Janus Henderson Group PLC now owns 2,576,756 shares of the medical instruments supplier’s stock worth $367,625,000 after purchasing an additional 103,220 shares during the last quarter. Millennium Management LLC lifted its stake in ICU Medical by 173.4% in the third quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock worth $130,638,000 after purchasing an additional 690,694 shares during the last quarter. State Street Corp boosted its position in ICU Medical by 2.8% during the fourth quarter. State Street Corp now owns 942,670 shares of the medical instruments supplier’s stock valued at $134,491,000 after buying an additional 25,545 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in ICU Medical by 5.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 920,776 shares of the medical instruments supplier’s stock valued at $131,370,000 after buying an additional 47,783 shares during the period. 96.10% of the stock is currently owned by institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.